The animal study portion of the GLP-compliant repeated dosing toxicity test for the anti-HIV antibody related to jointly held patents has finished. The final report is being compiled by the institution, and NOAEL assessments will be confirmed after receipt and review. Going forward, consultations with PMDA and preparation for clinical trials will proceed. The impact on consolidated results for the fiscal year ending March 2026 is unknown at this time.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4570","jir_company_name":"ACME Immunobiology Institute Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4570-20260826-01.pdf","jir_short_summary":"The animal study portion of the GLP-compliant repeated dosing toxicity test for the anti-HIV antibody related to jointly held patents has finished. The final report is being compiled by the institution, and NOAEL assessments will be confirmed after receipt and review. Going forward, consultations with PMDA and preparation for clinical trials will proceed. The impact on consolidated results for the fiscal year ending March 2026 is unknown at this time.","jir_summary":"### Key points of the news\nRegarding jointly held patents, the GLP-compliant repeated dosing toxicity animal study conducted by CURED has ended as planned. The final report is being compiled by the institution, and assessments such as NOAEL will be finalized after receipt and review of the report. Going forward, preparations for initiating clinical trials will proceed in coordination with CURED, including consultations with PMDA. Direct impact on consolidated results for the fiscal year ending March 2026 is unclear.\n\n### Outlook \/ Impact\nAfter receipt of the final test report, contents will be reviewed and disclosed as appropriate. Preparations for initiating trials will progress in coordination with CURED. If there are matters to disclose, they will be released promptly. At this time, no financial impact is expected for the fiscal year ending March 2026, but effects may arise depending on trial progress and regulatory developments.","jir_financial_highlights":"Impact on consolidated results: Unknown (Unknown)\nReceipt and review of final test report: Due (In progress)","jir_category":"","jir_hashtags":"#IMMUNE_BIO_CONDUCT, #ClinicalTrialPreparationStatus","jir_key_figures":"NOAEL assessment finalization timing: after receipt and review of final report\nPreparations for clinical trial initiation: planned\nImpact on consolidated results for the fiscal year ending March 2026: Unknown","jir_meta_title":"\u3010ACME Immunobiology Institute Limited\u3011Notice of GLP anti-HIV antibody test completion | August 2026","jir_meta_description":"Animal study portion of the GLP-compliant repeated dosing toxicity test for the anti-HIV antibody has concluded. The final report is being compiled, and NOAEL assessments will be confirmed after receipt and review. Preparing for clinical trials; impact on fiscal year ending March 2026 is unknown.","jir_og_title":"\u3010ACME Immunobiology Institute Limited\u3011GLP test phase completion notice","jir_og_description":"Animal study of the GLP-compliant repeated dosing toxicity test for the anti-HIV antibody has been completed. The final report is currently being compiled. Preparations for initiating trials are underway, with financial impact undetermined.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58169,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-107232","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n